SEC Company Response from AIxCrypto Holdings, Inc. (AIXC) (CIK 0001460702) (FFR) — Jul 30, 2019

AIxCrypto Holdings, Inc. (AIXC) (CIK 0001460702)
Date: July 30, 2019 · CIK: 0001460702 · Accession: 0001493152-19-011343

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

July 30, 2019

Author

Chief

Form

CORRESP

Company

AIxCrypto Holdings, Inc. (AIXC) (CIK 0001460702)

Letter

Ritter Pharmaceuticals, Inc.

Century Park East, Suite 1000

Los Angeles, CA 90067

(310) 203-1000

July 30, 2019

VIA EDGAR

United States Securities and Exchange Commission

F Street, NE

Washington, D.C. 20549

Attention: Julia Griffith

Re:

Ritter Pharmaceuticals, Inc. – Request for Acceleration

Registration Statement on Form S-3

File No. 333- 232798

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Ritter Pharmaceuticals, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333- 232798) (the “Registration Statement”), so that it may become effective at 4:30 p.m. Eastern Standard Time on August 1, 2019, or as soon thereafter as practicable.

The Registrant hereby authorizes each of Wendy Grasso, Esq., Aron Izower, Esq. and Michael Sanders, Esq. of Reed Smith LLP, attorneys for the Registrant, to orally modify or withdraw this request for acceleration.

The Registrant requests that it be notified of such effectiveness by a telephone call to Wendy Grasso at (212) 549-0216 or, in her absence, Mr. Izower at (212) 549-0393 or Mr. Sanders at (310) 734-5232.

RITTER PHARMACEUTICALS, INC.

By: /s/ Andrew J. Ritter

Andrew J. Ritter

Chief Executive Officer

Show Raw Text

CORRESP
1
filename1.htm

Ritter
Pharmaceuticals, Inc.

1880
Century Park East, Suite 1000

Los
Angeles, CA 90067

(310)
203-1000

July
30, 2019

VIA
EDGAR

United
States Securities and Exchange Commission

100
F Street, NE

Washington,
D.C. 20549

Attention:
Julia Griffith

    Re:

    Ritter
Pharmaceuticals, Inc. – Request for Acceleration

    Registration
    Statement on Form S-3

    File
    No. 333- 232798

Ladies
and Gentlemen:

Pursuant
to Rule 461 promulgated under the Securities Act of 1933, as amended, Ritter Pharmaceuticals, Inc. (the “Registrant”)
hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333- 232798) (the “Registration
Statement”), so that it may become effective at 4:30 p.m. Eastern Standard Time on August 1, 2019, or as soon thereafter
as practicable.

The
Registrant hereby authorizes each of Wendy Grasso, Esq., Aron Izower, Esq. and Michael Sanders, Esq. of Reed Smith LLP, attorneys
for the Registrant, to orally modify or withdraw this request for acceleration.

The
Registrant requests that it be notified of such effectiveness by a telephone call to Wendy Grasso at (212) 549-0216 or, in her
absence, Mr. Izower at (212) 549-0393 or Mr. Sanders at (310) 734-5232.

    RITTER
    PHARMACEUTICALS, INC.

    By:
    /s/
    Andrew J. Ritter

    Andrew
    J. Ritter

    Chief
    Executive Officer

SecProbe.io